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Abstract
There is a long-standing paradox that N-methyl-D-aspartate receptors (NMDARs) can both
promote neuronal health and kill neurons. Recent studies show that NMDAR-induced responses
depend on the receptor location: stimulation of synaptic NMDARs, acting primarily through
nuclear Ca2+ signaling, leads to the build-up of a neuroprotective ‘shield’, whereas stimulation of
extrasynaptic NMDARs promotes cell death. These differences result from the activation of
distinct genomic programmes and opposing actions on intracellular signalling pathways.
Perturbations in the balance between synaptic and extrasynaptic NMDAR activity contribute to
neuronal dysfunction in acute ischaemia and Huntington’s disease and could be a common theme
in the aetiology of neurodegenerative diseases. Neuroprotective therapies should aim to both
enhance the effect of synaptic activity and disrupt extrasynaptic NMDAR-dependent death
signalling.
Introduction
NMDARs (N-methyl-D-aspartate (NMDA) receptors) are cation channels that are gated by
the neurotransmitter glutamate. They are essential mediators of many forms of synaptic
plasticity and also mediate aspects of development and synaptic transmission1, 2. In addition
to their synaptic localization, NMDARs are found at extrasynaptic and perisynaptic sites,
which can be defined immunohistochemically (e.g. distal from the post-synaptic density,
PSD) and electrophysiologically (e.g. out of reach of normal synaptic glutamate release, see
Box 1). In immature hippocampal neurons, extrasynaptic NMDARs can represent up to
three quarters of all NMDARs3. Although the proportion of synaptically located NMDARs
increases with development, a significant population of NMDARs remain extrasynaptic in
adulthood3-6. The exact location of extrasynaptic NMDARs had not been thoroughly
addressed until recently6. Only around one quarter of extrasynaptic NMDARs in adult
hippocampal slices are classified as being perisynaptic (that is, within 100 nm of the PSD),
the rest being localized on dendrites or on non-perisynaptic parts of the spine. Of the
dendritically localized extrasynaptic NMDARs, around one third are adjacent to glia-like
processes, and around half are adjacent to axons. The physiological function of
extrasynaptic NMDARs is not fully understood, but their activation by glutamate spillover
may contribute to long-term depression 7-9. This Review will focus on the emerging role of
extrasynaptic NMDARs in pathological scenarios, in contrast with the demonstrated
survival-promoting effects of synaptic NMDAR activity.
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We first discuss the background to the field of excitotoxicity, the dichotomous nature of
NMDAR signalling, and the evidence that receptor location plays a role in this dichotomy.
We then outline the molecular mechanisms that underlie synaptic NMDAR-dependent
neuroprotection and the various pathways that are coupled preferentially to extrasynaptic
NMDARs. After discussing the potential basis for differential signalling by synaptic versus
extrasynaptic NMDARs we review recent studies that address the relevance of synaptic
versus extrasynaptic NMDAR signalling in acute and chronic neurological disorders,
focusing on stroke and Huntington’s disease. Finally we examine prospects for therapies
designed to selectively target extrasynaptic NMDAR signalling while sparing synaptic
signalling.
The ‘NMDAR paradox’
The neurotoxicity of sustained glutamate exposure to retinal neurons was first reported over
50 years ago10, at around the same time as the excitatory properties of glutamate were being
characterized11. Later, Olney showed that glutamate toxicity was not restricted to retinal
neurons, and coined the term “excitotoxicity” 12. Choi subsequently demonstrated that Ca2+
entry was a key mediator of glutamate excitotoxicity, and that the NMDAR was the primary
source of toxic Ca2+ influx 13-15. Shortly after, it was proposed that Ca2+ entry through
NMDARs was particularly effective at killing neurons compared to entry through other
channels 16. At the same time, evidence was accumulating that implicated glutamate toxicity
and NMDAR activity in acute neurological trauma such as stroke, as well as circumstantial
evidence pointing to a role for glutamate toxicity and NMDAR activity in chronic
neurodegenerative diseases, including Huntington’s disease 17-19. Since then, the work of
many laboratories have advanced our understanding of how glutamate dyshomeostasis, ionic
imbalance and abnormal NMDAR activity can contribute to such disorders 19-24.
The destructive effects of NMDAR activity are in striking contrast to the observation that
the survival of several types of neuron is dependent on synaptic NMDAR activity and
function25-27. Elimination of NMDAR activity in vivo causes widespread apoptosis and
enhances trauma-induced injury in developing neurons28-32. In the adult CNS, NMDAR
blockade exacerbates neuron loss when applied after traumatic brain injury (TBI) or during
ongoing neurodegeneration33, and impairs the survival of newborn neurons in the adult
dentate gyrus34. Thus, NMDARs are important for cell survival but can also be harmful and
kill neurons. For many years it was thought that the degree of Ca2+ entry though NMDARs
was solely responsible for these differences in cellular outcome: moderate levels of
NMDAR activity were considered to be beneficial for neurons, whereas excessive activation
of NMDARs, with subsequent ‘Ca2+ overload’ of the neurons, was deleterious. According
to this model, neuronal responses to NMDAR activity followed a bell-shaped curve, where
both too much and too little was potentially harmful35-37.
This view may be subject to revision in light of recent work that has revealed an alternative
explanation for the ‘NMDAR paradox’, namely that it is the location of the NMDAR that
also influences whether it is coupled to pro-death or pro-survival signals. According to this
new model, synaptic NMDARs are neuroprotective, whereas extrasynaptic NMDARs
preferentially initiate cell death pathways. Thus, the fate of neurons is not determined solely
by the degree of overall NMDAR activity but by the extent to which synaptic and
extrasynaptic NMDARs are activated. This may be best described with an ‘χ-shaped’ graph
in which an ascending curve that represents increased neuroprotection due to increased
synaptic NMDAR activity is superimposed on a descending curve that illustrates the
progressive decrease in neuroprotection due to increasing extrasynaptic NMDAR activity
(Figure 1). According to this concept, it is not the ‘Ca2+-overload’ per se that is the sole
determinant of toxicity but rather the Ca2+ flow though NMDARs located outside the
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synapse that is particularly harmful to neurons. Synaptic NMDAR activity is by nature
phasic and extrasynaptic activation is achieved by chronic agonism, but when equivalent
overall Ca2+ concentrations are triggered by synaptic and extrasynaptic NMDARs, they
cause strikingly different downstream events38. Ca2+ influx evoked by intense synaptic
NMDAR activation is not only well tolerated by hippocampal neurons (i.e. it causes no
perturbations to mitochondrial membrane potential), it is also the trigger for genomic
processes that render neurons more resistant to apoptotic and oxidative insults38 (see below).
In sharp contrast, comparable Ca2+ transients induced by activation of extrasynaptic
NMDARs — either on their own or in the presence of synaptic NMDAR activation —
trigger mitochondrial dysfunction and cell death38.
The distinct synaptic versus extrasynaptic NMDAR signalling pathways that lead to survival
and death, respectively, were initially characterized in hippocampal neurons, and
subsequently were confirmed to exist in cortical neurons39. Recent studies have shown that a
selective activation of extrasynaptic NMDARs in hippocampal neurons triggers the same
amount of cell death as activation of all NMDARs (synaptic and extrasynaptic) despite the
fact that extrasynaptic NMDARs elicit a smaller initial Ca2+ elevation40, highlighting the
importance of extrasynaptic NMDARs in excitotoxicity. Moreover, several studies have
demonstrated that certain effects of extrasynaptic NMDAR signalling dominate over effects
of synaptic signalling38, 41-43. However, under chronic conditions of NMDAR activation,
the balance between synaptic and extrasynaptic NMDAR activity is important 44 and can
influence the point at which escalating levels of bath-applied NMDA or glutamate become
neurotoxic. For example, bath application of low concentrations of NMDA can induce firing
activity and so preferentially activate synaptic pathways and activity-dependent
neuroprotection, whereas higher levels of NMDA suppress firing, resulting in extrasynaptic
pathways dominating 45.
Synaptic NMDAR-dependent neuroprotection
According to the theory of neuronal health46, neurons can exist in a spectrum of states
ranging from fully functioning and resilient at one extreme to dysfunctional and vulnerable
to insults at the other extreme. The position of the neuron within this spectrum is influenced
by a multitude of signals and stimuli, but is known to be shifted towards health and
robustness by synaptic NMDAR activity. An episode of synaptic NMDAR activity promotes
neuroprotection that lasts beyond the duration of the episode and continues after most
signalling pathways are no longer active47. This long-lasting form of ‘acquired
neuroprotection’ predominantly results from changes in gene expression that have effects at
multiple levels within the cell (Figure 2) such as enhancement of mitochondrial health,
boosting of antioxidant defences and suppression of caspase activation, all of which in turn
serve to preserve neuronal function and improve viability in the face of insults.
Induction of survival genes
Ca2+ signalling is a major mediator of the dialogue between the synapse and cell nucleus. It
has been known for over 20 years that seizure activity triggers transcriptional responses in
neurons 48, as do physiological patterns of synaptic NMDAR activity, such as those that
promote synaptic potentiation 49. Ca2+ entry through synaptic NMDARs is augmented by
release from internal stores, after which Ca2+ is transduced to the cell soma where it invades
the nucleus 50. Nuclear Ca2+ is one of the most potent activators of neuronal gene
expression. Transcriptome analyses have revealed that in hippocampal neurons nearly 200
genes are controlled by nuclear Ca2+ signalling42, 51.
One important target of nuclear Ca2+ is the nuclear Ca2+/calmodulin-dependent protein
(CaM) kinase IV and the transcription factor cyclic-AMP response element binding protein
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(CREB, Figure 3a–pathways A-D)52-58. CREB is the prototypical signal-regulated
transcription factor, whose role in neuronal survival, as well as in several other processes
(including synaptic plasticity, addiction, neurogenesis, and learning and memory), is well
documented59-62,63. In hippocampal neurons, CREB-dependent gene expression is causally
linked to the long-lasting phase of activity-dependent neuroprotection against apoptotic and
excitotoxic insults47, 64. This form of acquired neuroprotection is dependent on nuclear Ca2+
signalling47, which is consistent with the known role for nuclear Ca2+ in CREB activation50,
57
, 
65
. In recent years, the genomic programmes that underlie acquired neuroprotection have
been uncovered42, 51. Among the pool of nuclear Ca2+-regulated genes, a core set of ten
genes, termed Activity-regulated inhibitors of death (AID) genes have been identified,
which have been shown to provide neurons with a broad-spectrum neuroprotective ‘shield’,
both in cell culture and in animal models of neurodegeneration51. Some of the AID genes,
which include the genes encoding activating transcription factor 3 (Atf3), B-cell
translocation gene 2 (Btg2), B-cell lymphoma 6 (Bcl6), growth arrest and DNA damage
induced gene 45 beta (GADD45beta), growth arrest and DNA damage induced gene 45
gamma (GADD45gamma), Inhibin beta-A (Inhba), Interferon activated gene 202B
(Ifi202B), neuronal PAS domain protein 4 (Npas4), nerve growth factor IB (also known as
nuclear receptor subfamily 4, group A, member 1) (Nr4a1), and serine protease inhibitor B2
(Serpinb2), seem to be potential CREB target genes and may provide neuroprotection
through a common process that renders mitochondria more resistant to cellular stress and
toxic insults (Figure 4a)42, 51, 66, 67. Another target of synaptic NMDAR and nuclear Ca2+-
CREB signalling is the gene that encodes the neurotrophin brain-derived neurotrophic factor
(Bdnf)38, 51, 68, 69. BDNF has neuroprotective properties70 and can rescue neurons from
NMDAR blockade-induced neuronal death71.
Although CREB is a key mediator of nuclear Ca2+-dependent neuroprotection, other
transcription factors implicated in mediating NMDAR-dependent survival may also be
partly controlled by nuclear Ca2+, such as nuclear factor of activated T-cells (NFAT72). By
contrast, NMDAR-dependent activation of other neuroprotective factors such as nuclear
factor I, subtype A (NFI-A) might occur independently of nuclear Ca2+ elevation (its
activation being dependent on the extracellular signal-regulated kinase 1/2 (ERK1/2)
pathway and nitric oxide (NO) synthesis73).
Suppression of death genes
A second mechanism through which synaptic NMDAR activity restricts the apoptotic
potential of a neuron involves the transcriptional suppression of core components of the
intrinsic apoptosis cascade (Figure 4a)66, 67. Synaptic NMDAR activity suppresses the
expression of the pro-apoptotic Bcl-2 homology domain3 (BH3)-only member gene Puma in
vitro and in vivo66, 67. Puma expression is both sufficient to induce cell death and necessary
for apoptotic death in response to NMDAR blockade67. As with activation of CREB,
suppression of Puma is specific to synaptic NMDAR signalling, as bath activation of all
NMDARs (synaptic and extrasynaptic) fails to influence Puma expression. Suppression of
Puma inhibits the apoptotic cascade upstream of cytochrome c release, but auxiliary
protective mechanisms also exist downstream, as the genes encoding the core apoptosome
components apoptotic protease activating factor 1 (Apaf-1) and pro-caspase-9 are also
subject to transcriptional suppression by synaptic NMDAR activity66, 67. The net effect of
all these transcriptional changes is that the activation of caspase-9 and downstream
executioner caspases is very limited, apoptosis is inhibited, and the neurons remain viable
and electrically active 67.
Synaptic NMDAR activity also suppresses the expression and/or activity of important pro-
death transcription factors (Figure 3b, Figure 4a). The forkhead box O (FOXO) class of
transcription factors can promote neuronal death following excitotoxic injury, trophic factor
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withdrawal and oxidative stress74-77. Known pro-death FOXO target genes include the
BH3-only genes Noxa, Bcl2-like protein 11 (Bcl2l11, also known as Bim) and Puma, Fas
ligand (Fasl) and thioredoxin-interacting protein (Txnip). In conditions of trophic
deprivation, in which FOXOs are constitutively located in the nucleus, synaptic NMDAR
activity promotes sustained activation of the Akt pathway, leading to the phosphorylation
and nuclear export of FOXO and the subsequent inactivation of FOXO target genes, which
includes Foxo1 (Foxo1 itself was recently identified as a FOXO target gene43, 78, Figure
3b–pathway A). Furthermore, synaptic NMDAR activity induces a long-lasting inhibition of
FOXO nuclear import77 (Figure 3b–pathway D). This long-lasting blockade was shown to
require nuclear CaM kinase IV activation and de novo gene expression, although the exact
mechanism by which this leads to blockade of FOXO nuclear import remains unclear. Thus,
synaptic NMDAR activity both promotes the nuclear export of FOXOs and the
transcriptional suppression of Foxo1 and places a long-lasting blockade on FOXO nuclear
translocation (Figure 3b). p53 is another pro-apoptotic transcription factor that is subject to
negative transcriptional regulation by synaptic NMDAR activity and that may contribute to
the suppression of Apaf-166, although p53-independent routes to Apaf-1 expression also
exist67.
Protection against oxidative stress
In addition to apoptosis-suppressing effects, synaptic NMDAR activity also enhances
antioxidant defences43 (Figure 2, Figure 4b), which contributes to neuroprotection against
oxidative insults. NMDAR blockade in vivo triggers neuronal death that is associated with
protein carbonylation (a marker of oxidative stress), which is suggestive of a role for
physiological NMDAR activity in supporting antioxidant defences. Synaptic NMDAR
activity also controls neuronal vulnerability to oxidative stress-induced death in vitro43. It
triggers a number of changes to the thioredoxin-peroxiredoxin system that contribute to this
neuroprotective effect. Specifically, synaptic activity enhances thioredoxin activity and
facilitates the reduction of hyperoxidized peroxiredoxins, which are an important class of
antioxidant enzymes. These effects are mediated by a coordinated programme of gene
expression changes, some of which have been characterized43. These changes include the
transcriptional suppression of the FOXO target gene Txnip, which is dynamically regulated
by NMDAR activity in vitro and in vivo. Also, enhanced reduction of hyperoxidized
peroxiredoxins is associated with transcriptional activation of two genes, Srxn1
(sulfiredoxin) and Sesn2 (sestrin 2). The products of these genes can mediate this
reaction79-81, with sulfiredoxin induction likely to be more important82, 83. Trans-synaptic
stimulation of synaptic NMDARs is crucial for boosting antioxidant defences, as chronic
bath activation of all (synaptic and extrasynaptic) NMDARs failed to trigger the
aforementioned transcriptional changes or protect against oxidative insults.
The gene expression changes (Figure 4b) do not account for all the antioxidant effects of
synaptic NMDAR activity, raising the possibility that other antioxidant systems, such as the
glutathione system, may also be subject to control by synaptic NMDAR activity.
Pro-death signalling by extrasynaptic NMDARs
NMDAR-dependent neuron death is mediated by a variety of pathways, the relative
contribution of which may depend on the cell type, the developmental stage or intensity of
the excitotoxic insult20, 84. Recent studies have found that certain pro-death pathways or
events are preferentially activated by extrasynaptic NMDARs compared to synaptic ones
(Figure 5). As discussed below, in some cases this involves direct antagonism of synaptic
NMDAR-activated survival pathways, whereas in others it involves the triggering of events/
pathways that are simply not activated by synaptic NMDARs.
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CREB shut-off
Bath activation of NMDARs has long been known to be a poor activator of CRE-dependent
gene expression in hippocampal neurons, compared to Ca2+ entry though voltage-gated Ca2+
channels (although activation of the serum response element (SRE) was equally good)85.
This could be explained by the fact that bath activation of NMDARs induces CREB-
activating phosphorylation of CREB at serine-133, followed shortly afterwards by a strong
CREB-dephosphorylation signal 86, 87. By contrast, activation of voltage-gated Ca2+
channels induces sustained CREB phosphorylation 86. The fact that NMDARs seemed to be
poor inducers of CRE-dependent gene expression when they were bath-activated was at
apparent odds with the fact that NMDARs were known to induce activation of CRE-
dependent gene expression following electrical activity 49, 88. These historical observations
can be explained by the observation that synaptic NMDAR activity promotes sustained
CREB phosphorylation, whereas extrasynaptic NMDARs are coupled to a dominant CREB
dephosphorylating signalling pathway 38, 89 (Figure 3a). When all (synaptic and
extrasynaptic) NMDARs are activated by bath-applied glutamate or NMDA, the
extrasynaptic pathway dominates, resulting in weak CREB activation 38, 85, 86. The only
exception is when low levels of bath-applied NMDA induce firing activity, in which case
synaptic signalling dominates and CREB activation is relatively strong 45.
Recently, insight into the mechanistic basis of this differential signalling was uncovered and
found to be centred on Jacob, a binding partner of the neuronal Ca2+ binding protein
caldendrin90. Jacob, when localized to the nucleus, causes CREB dephosphorylation and
also promotes a loss of synaptic contacts. Jacob contains a nuclear localization signal and its
nuclear import requires importin-α binding. This binding and nuclear import is prevented by
caldendrin, which binds Jacob in a Ca2+-dependent manner. Synaptic NMDAR activity was
shown to promote caldendrin-dependent retention of Jacob outside of the nucleus, whereas
extrasynaptic NMDAR activity promoted the nuclear accumulation of Jacob, with
subsequent effects on neuronal survival 90 (Figure 3a–pathway F). As the coupling of
extrasynaptic NMDA receptors to a CREB shut-off pathway is developmentally regulated
and absent in very young neurons 89, it will be of interest to know whether there is a
developmental switch that activates the Jacob pathway.
ERK1/2 inactivation
The ERK1/2 pathway, which can support activation of CREB and inactivate the pro-death
protein Bcl-2-associated death promoter (BAD) has been implicated in NMDAR-dependent
neuroprotection,26. Synaptic NMDAR activity promotes sustained ERK activity47, 91,
whereas activation of all NMDARs by bath application of NMDA results in ERK activation
that is followed by inactivation91-93. The basis for this bi-directional control of ERKs turned
out to be due to the opposing actions of synaptic versus extrasynaptic NMDARs41. Synaptic
NMDARs couple to activation, whereas extrasynaptic NMDARs promote ERK
dephosphorylation and subsequent inactivation in both hippocampal41 and cortical
neurons39 (Figure 3a–pathway E). Consistent with this, extrasynaptic NMDARs strongly
inactivate Ras (upstream of ERK) 93. Thus, synaptic and extrasynaptic NMDARs are
mutually antagonistic with regard to Ras-ERK signalling. However, ERK1/2 inactivation by
extrasynaptic NMDAR is stimulus-specific: although extrasynaptic NMDARs exert an
ERK1/2 shut-off signal that is dominant over that triggered by activation of synaptic
NMDARs, it does not antagonize ERK1/2 activity induced by BDNF94.
FOXO activation
Synaptic NMDAR activity inactivates pro-death FOXOs at multiple levels (see above and
Figure 3b), whereas extrasynaptic NMDAR activity does the opposite. Chronic activation of
all (synaptic and extrasynaptic NMDARs) does not result in FOXO export from the nucleus,
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because activation of Akt is not sustained43 (Sustained activation of the Akt pathway leads
to the phosphorylation and nuclear export of FOXO). More recently, it was shown that
extrasynaptic NMDAR-evoked signals not only fail to induce FOXO nuclear export, but
instead promote the nuclear import of FOXOs that are normally sequestered in the
cytoplasm77 (Figure 3b–pathway C). This activation of FOXOs subsequently contributes to
NMDAR-dependent neuronal death. Thus, the activation status of FOXOs is highly sensitive
to the balance between synaptic and extrasynaptic NMDAR activity (Figure 3b).
Calpain activation and STEP cleavage
Activation of extrasynaptic NMDARs strongly activate calpains, whereas synaptic NMDAR
activity does not95. In agreement with this, the classical calpain substrate fodrin and Na+/
Ca2+ exchanger 3 (NCX3)95 are cleaved following extrasynaptic, but not synaptic, NMDAR
activity. NCX3 is known to be cleaved by calpains in animal models of stroke, leading to
delayed Ca2+ deregulation and neuronal death96. Another substrate for extrasynaptic
NMDAR-activated calpains is striatal enriched tyrosine phosphatase (STEP), which is
cleaved into a form that cannot interact with its normal substrates. One such substrate is p38
mitogen-activated protein (MAP) kinase, which is negatively regulated by STEP, is enriched
at extrasynaptic membrane fractions, and is known to contribute to death induced by chronic
NMDA or glutamate exposure in cerebellar granule cells and cortical neurons95, 97-99.
Inhibition of calpain-mediated STEP cleavage is sufficient to inhibit NMDAR-dependent
p38 activation and can protect neurons from glutamate toxicity and oxygen-glucose
deprivation95. Thus calpain — coupled to STEP cleavage and subsequent p38 activation —
represents another pro-death cascade that selectively activated by extrasynaptic NMDARs
(Figure 5). One important caveat to the role of p38 in excitotoxicity is that its influence on
survival and death is heavily context-dependent. For example, it can promote
neuroprotection through activation of myocyte enhancer factor 2 (MEF2) 100 and indeed can
be activated by neuroprotective, synaptic NMDAR activity 99, 101. Thus, its contribution to
neuronal death in excitotoxicity may rely on interactions with other events that are triggered
by the excitotoxic insult.
The observation that p38 is disinhibited by extrasynaptic NMDAR activity through STEP
cleavage also raises the question as to why extrasynaptic NMDARs fail to activate ERK1/2,
as STEP is also a powerful negative regulator of ERKs95, 102. It is possible that other,
dominant ERK-inactivating signals may be triggered in parallel (such as those discussed
above), overriding any effects of STEP cleavage.
Gene expression changes specifically induced by extrasynaptic NMDAR activity
As a result of these or other differences in signalling, extrasynaptic NMDAR activity
induces a very different programme of gene expression compared to synaptic NMDARs42.
As new gene expression contributes to at least some forms of excitotoxic neuronal death,
these changes are likely to be functionally important. Although the identity of such genes
remains to be elucidated, they may include FOXO target genes or other factors targeted by
extrasynaptic signals. For example, Clca1, the gene that encodes Ca2+ -activated chloride
channel regulator 1, is selectively activated by extrasynaptic NMDAR activity in cell culture
and in a stroke model, and its overexpression is sufficient to kill neurons42, 103, although the
mechanism by which its expression is induced is unclear.
New developments and ongoing questions
Control of nuclear architecture by synaptic and extrasynaptic NMDARs
In addition to differentially controlling specific transcription-regulating events, synaptic and
extrasynaptic NMDARs may also more globally affect signal processing towards and within
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the cell nucleus by regulating nuclear architecture. A structural analysis of hippocampal
nuclei using a novel algorithm for three-dimensional reconstruction uncovered that - in
contrast to what is commonly thought and what is depicted in virtually all textbooks - many
cell nuclei are not round or near-spherical organelles but have a very complex, highly
infolded shape 104. The structure of the nucleus is dynamic and signal-regulated, with
synaptic and extrasynaptic NMDARs having opposing effects: stimulation of synaptic
NMDARs increases the number of infolded nuclei, whereas the infolded shape is rapidly
lost following Ca2+ flux through extrasynaptic NMDARs. Thus, neurons translate NMDAR
signals into changes in nuclear geometry, providing a means for an activity-dependent
modulation of nucleo-cytoplasmic exchange of molecules and ions 104. The changes in
nuclear shape and consequent rearrangements of the nuclear architecture and spatial re-
organization of chromosome territories may affect chromatin structures and accessibility and
could have profound effects on gene expression and genome stability. In addition, infolded
and near-spherical nuclei have similar volumes but infolded nuclei have a larger surface and
larger number of nuclear pore complexes 104. Given that actively transcribed DNA segments
may be located near nuclear pore complexes 105, 106, a possible increase in the number of
nuclear pore complexes in infolded nuclei following synaptic NMDAR activation may
enhance the capacity of the nucleus for transcription-coupled anchoring of promoter regions
to nuclear pore complexes. Synaptic NMDAR-induced structural plasticity of the nucleus
may therefore represent an adaptation to a metabolically more active state with an increased
demand for gene expression.
The basis for differential synaptic versus extrasynaptic NMDAR signalling: outstanding
questions
The differences in signalling between synaptic and extrasynaptic NMDARs could
theoretically be due to one of three factors, or a combination thereof. Firstly, they could be
due to differences in the make-up of the NMDAR signalling complexes at extrasynaptic
compared to synaptic locations. The components that make up the NMDAR signalling
complex in the post-synaptic density are the subject of intense study107, but the molecules
that associate with extrasynaptic NMDARs have been poorly characterized. Some proteins
that are found in synapses and that are linked to synaptic NMDARs, such as the membrane-
associated guanylate kinases (MAGUKs) postsynaptic density protein (PSD)-95 and
PSD-93, discs, large homolog 1 (Drosophila) (DLG1, also known as SAP97, and discs, large
homolog 3 (Drosophila) (DLG3, also known as SAP102), are also linked to extrasynaptic
NMDARs. In 3-week old hippocampal cultures, around 20% of extrasynaptic NMDARs
were found to be associated with PSD-95 and a further 20% with SAP1026. Association of
extrasynaptic GluN1 NMDAR subunits with MAGUKs was also observed by double-
labelling immuno-gold electron microscopy in adult hippocampal slices 6. This is of
particular interest since MAGUKs have been implicated in coupling the NMDAR to
downstream death pathways such as excessive nitric oxide production 108, 109. Other studies
suggest the possibility of a specific association of extrasynaptic NMDARs with certain
proteins. For example, it has been postulated that, as caldendrin is localised to the post-
synaptic density, only trans-synaptic activation of synaptic NMDARs trigger local Ca2+
transients that are high enough to promote caldendrin-mediated Jacob retention90.
Alternatively, the preferential localization of p38 (but not ERK1/2) at extrasynaptic
membranes may explain its preferential activation by extrasynaptic NMDAR-dependent
STEP cleavage95. It is likely that other, yet to be identified proteins associate differentially
with synaptic/extrasynaptic NMDARs.
Secondly, receptor subunit composition could play a role in the differences in signalling
between synaptic and extrasynaptic NMDARs. The cytoplasmic C-termini of the GluN2
subunits have undergone considerable sequence divergence through evolution, which
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potentially allows for differential association of signalling molecules. During development
GluN2B is the predominant subunit at all synaptic and extrasynaptic locations in forebrain
neurons, and GluN2A expression in the rodent CNS begins at the end of the first post-natal
week110, 111. In the adult forebrain both the GluN2A and GluN2B subunits are prevalent.
GluN2A becomes incorporated into synaptic NMDARs 112 and has been reported to become
enriched at synapses compared to extrasynaptic locations, with GluN2B more abundant at
extrasynaptic locations113, 114. No studies, however, have demonstrated a clear-cut spatial
demarcation. Indeed, GluN2A subunits have been identified at extrasynaptic sites in cultured
neurons115 and the subunit compositions of synaptic and extrasynaptic NMDARs in 3-week-
old acute hippocampal slices have been found to be very similar116. Moreover,
immunofluorescence and immuno-gold studies have also identified both GluN2A and
GluN2B at extrasynaptic locations6.
Nevertheless, subunit differences could have a contributing effect if GluN2A- and GluN2B-
containing NMDARs are coupled differently to pro-survival and pro-death pathways.
Indeed, GluN2B or GluN2A-containing NMDARs have been proposed to promote neuronal
death and neuronal survival, respectively117. However, the specificity of the GluN2A-
specific antagonist used in this study117 has been questioned, particularly when employed in
vivo or in non-steady state conditions118-122. Moreover, it has been shown that GluN2B-
and GluN2A-containing NMDARs can both promote survival and death43, 114, 123. Whether
they do so with differing efficiencies, however, remains unclear as a direct comparison has
yet to be made. Indeed, attempting to do so would be challenging given the lack of a
sufficiently selective GluN2A-specific antagonist. Also, the fact that GluN2B and GluN2A
are expressed at different relative levels in development can cloud the issue, as
developmental changes in NMDAR signalling can be misinterpreted as being due to a
switch in GluN2 subunit when there are in fact many other potential explanations. Another
important issue is that receptors can exist in a tri-heteromeric form that contains both a
GluN2A and a GluN2B subunit 124, meaning that 2A- and 2B-dependent signals can
theoretically be transduced from the same channel. Whether the GluN2 subunit (and
particularly its C-terminus) influences whether an activated NMDAR will promote either
survival or death will require more sophisticated approaches in order to be fully resolved.
A final potential factor contributing to differential signalling could be the way in which
synaptic and extrasynaptic NMDAR pools are activated. Synaptic NMDARs are generally
transiently and intensely activated by the trans-synaptic release of glutamate, while
extrasynaptic NMDARs are typically activated chronically, by elevated levels of ambient
glutamate. Subtle differences in the spatial properties of intracellular Ca2+ transients evoked
by these stimuli could differentially affect signalling, even if the overall Ca2+ load were
similar. If trans-synaptic versus chronic activation of NMDARs is a contributing factor in
differential synaptic vs. extrasynaptic NMDAR signalling, this raises the question as to
whether synaptic NMDARs can contribute to excitotoxic neuronal death under certain
circumstances (e.g. chronic activation). Against this idea is the observation that prior
blockade of synaptic NMDARs was not protective against NMDA-induced death 40.
Nevertheless, it is a possibility that under certain conditions where extrasynaptic NMDARs
are chronically active, that chronic activation of synaptic NMDARs may contribute to a
toxic Ca2+ load. Conversely, it is unclear whether extrasynaptic NMDARs can contribute to
neuroprotective signalling under certain circumstances. For example, if strong synaptic
activity results in the transient trans-synaptic activation of a portion of perisynaptic or
extrasynaptic receptors (as has been shown 125), does this contribute to neuroprotective
signalling or antagonize those promoted by synaptic NMDAR activation? It is also not clear
what proportion of a cell’s extrasynaptic NMDAR population need to be activated in order
to promote pro-death signalling.
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Another, related question is whether extrasynaptic NMDARs at different locations
(dendritic, perisynaptic, cell body) signal differently. Studies have shown NMDARs
demonstrating mobility between synaptic and extrasynaptic locations 113, 151, 154 (see Box
1), and it remains to be determined whether these receptors alter their signalling properties
upon switching their location. One possibility is that an NMDAR moving (for example)
between an extrasynaptic to a synaptic site, encounters a different biochemical environment
and so associates with a different complement of downstream signalling molecules.
However, the extent to which NMDARs are mobile in vivo remains to be clarified in the
light of recent observations that synaptic and extrasynaptic NMDARs from stable pools in
acute slices 116.
Addressing the above questions will enhance our knowledge about the molecular basis for
differential synaptic vs. extrasynaptic NMDAR signalling, and enhance our understanding
of the precise conditions that determine the balance between protective and destructive
NMDAR signalling.
Clinical implications
Extrasynaptic NMDARs in ischaemic stroke
Inappropriate levels of NMDAR activity can contribute to neuronal death or dysfunction in a
number of paradigms, including acute excitotoxic insults (e.g. stroke, TBI) and certain
neurodegenerative diseases, such as HD and AD (reviewed in23, 24, 126). Recent work has
specifically implicated extrasynaptic NMDAR activation in the aetio-pathophysiology
associated with an acute and a chronic form of neuronal dysfunction (ischaemic stroke and
HD, respectively).
During an ischaemic episode, extracellular glutamate accumulates due to synaptic release
and impairment or reversal of uptake mechanisms22, 127, and neurons become depolarized,
relieving the Mg2+ blockade of NMDARs. These events have the combined effect of
causing strong activation of NMDARs128, possibly including those located outside the
synapse. The consequences of reversed uptake can be studied in culture through the use of
the transportable glutamate transport inhibitor L-trans-pyrrolidine-2,4-dicarboxylate (PDC),
which causes reversed glutamate uptake through hetero-exchange129. In neuron/astrocyte
co-cultures, PDC treatment causes glutamate efflux and excitotoxicity due to an activation
of extrasynaptic NMDARs that mainly arises from reversed astrocytic uptake130.
Interestingly, a significant proportion of extrasynaptic NMDARs in vivo are located
adjacent to glia6, raising the possibility that astrocytic glutamate release may lead to
activation of these receptors.
A recent study has demonstrated that extrasynaptic NMDAR activity may be selectively
enhanced in ischaemia via an intracellular signalling cascade131. Ischaemia recruits death-
associated protein kinase (DAPK1) directly to the C-terminal tail of GluN2B, leading to
phosphorylation of the channel and increased single-channel conductance. The effect is
specific to GluN2B-containing NMDARs and results in a selective enhancement of
extrasynaptic NMDAR currents131, which is not observed in DAPK1-deficient neurons.
Moreover, peptide-mediated disruption of DAPK1–NMDAR interactions was shown to
protect neurons against oxygen-glucose deprivation in vitro and ischaemic damage in
vivo131. Taken together, these studies indicate that extrasynaptic NMDAR activity
contributes to ischaemic neuron loss.
Synaptic and extrasynaptic NMDARs in Huntington’s Disease
Recent studies show that the relationship between extrasynaptic NMDAR signalling and
mutant Huntingtin (mtHtt) may be a key factor in HD progression44, 132 (Figure 6a). One
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study focused on the presymptomatic YAC128 transgenic mouse, which expresses a mutant
huntingtin (mtHtt) that contains 128 CAG repeats, as compared to a YAC18 control mouse
which expresses Htt with a non-pathological CAG repeat length132. Although expression of
mtHtt had no effect on synaptic NMDAR activity, YAC128 transgenic mice showed both an
increase in extrasynaptic NMDAR current and in extrasynaptic NMDAR expression
specifically in striatal medium spiny neurons. This enhanced extrasynaptic NMDAR activity
was dominated by GluN2B-containing NMDARs and persisted in aged YAC128 mice132.
Consistent with the previously mentioned coupling of extrasynaptic NMDAR activity to
CREB dephosphorylation and inactivation 38, reduced CREB phosphorylation was observed
in the striatum of YAC128 mice132.
In addition to the influence of mtHtt on extrasynaptic NMDAR function, a recent study has
demonstrated that synaptic and extrasynaptic NMDAR signalling have distinct and opposing
effects on the neurotoxicity of mtHtt itself. Synaptic NMDAR activity reduces mtHtt
toxicity by increasing the formation of non-toxic mtHtt inclusions by a process involving the
transcriptional up-regulation of the chaperonin TRiC (T complex-1 ring complex) subunit
TCP1. TCP1 knock-down or blocking of synaptic activity reduced the formation of
inclusions, rendering neurons vulnerable to mtHtt-induced neuronal death. This mtHtt-
induced neuronal death is itself dependent on extrasynaptic NMDAR activity44, which is
consistent with the upregulation of extrasynaptic NMDAR currents that have been observed
in YAC128 mice132 and, indeed, with the large body of literature implicating excessive
NMDAR-dependent activity in HD pathology23.
In addition to the enhancement of extrasynaptic NMDAR activity by mtHtt and in mediating
mtHtt-induced excitotoxic death, extrasynaptic NMDARs may also serve as up-stream
regulators of mtHtt toxicity44. Extrasynaptic NMDAR activity was found to support the
expression of Rhes, a small GTPase that controls the sumoylation of mtHtt, a modification
that promotes mtHtt toxicity and prevents its aggregation133.
Part of the toxic effects of mtHtt and excessive extrasynaptic NMDAR activity in HD
pathology may be attributable to the suppression of pro-survival CREB target gene
expression. As stated above, extrasynaptic NMDAR activity is coupled to a CREB-
inactivating dephosphorylation signal38. Consistent with this, CREB phosphorylation levels
are reduced in the striatum of YAC128 mice (where extrasynaptic NMDAR activity is
elevated)132. Also, mtHtt can suppress CREB-mediated gene expression by sequestering the
CREB coactivator CBP — an effect that contributes to mtHtt toxicity134, 135. A key
neuroprotective CREB target gene whose underexpression is implicated in HD pathogenesis
is the transcriptional coactivator peroxisome proliferator-activated receptor-γ coactivator 1a
(PGC-1α)136. In neurons, PGC-1α regulates both mitochondrial density and antioxidant
defences, and controls vulnerability to excitotoxic insults by these or other mechanisms101,
137
, 
138
. MtHtt interferes with CREB-dependent PGC-1α expression, and this leads to
mitochondrial dysfunction and metabolic defects139, 140. Indeed, PGC-1α expression is
lower in the striatum of human HD patients, but not in the cerebellum or hippocampus,
which is consistent with the brain areas associated with HD pathology. As a further
exacerbating factor, the striatum seems to be particularly vulnerable to loss of PGC-1α
expression141. Overexpression of PGC-1α protects both cortical and striatal neurons from
mtHtt- and 3-nitropropanoic acid-induced cell death, and lentiviral transduction of PGC-1α
into the striatum reduces striatal loss in a mouse model of HD44, 138-140.
Synaptic activity acts as a positive regulator of PGC-1α expression, both directly — via
CREB activation — and indirectly — by inhibiting mtHtt-dependent suppression of
PGC-1α (due to the aforementioned TCP1-dependent aggregation of mtHtt)44, 101.
Moreover, synaptic activity enhances PGC-1α’s transactivating capacity through a post-
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translational, p38-dependent mechanism101. Taken together, the balance between synaptic
and extrasynaptic NMDAR activity controls the toxicity of mtHtt and is itself controlled by
mtHtt (Figure 6a). This reciprocal, feed-forward control may play a key role in HD
progression and indicates that a selective blockade of extrasynaptic NMDARs and sparing
of synaptic NMDAR activity offers a potentially attractive therapeutic strategy, as outlined
below44, 132.
Therapeutic targeting of extrasynaptic NMDARs
Despite evidence from animal studies that have implicated NMDARs in ischaemic brain
damage, clinical trials of NMDAR antagonists for stroke and TBI have failed due to poor
tolerance and efficacy25, 142. The important role of NMDARs in the CNS may mean that for
many antagonists the maximum tolerated dose may not be therapeutically effective, as many
unacceptable side-effects are not off-target effects but are due to blockade of synaptic
NMDAR activity. Evidence that NMDAR activity can exert a neuroprotective effect has led
to suggestions that it may even promote recovery in the post-reperfusion phase, and prevent
delayed neuronal loss in the penumbra25, 143. Dichotomous signalling by NMDARs is also
evident in juvenile TBI. Here, treatment with NMDAR antagonists reduces primary
excitotoxic death but exacerbate secondary apoptosis, resulting in increased overall death30.
In adult TBI, the NMDAR has also been proposed to rapidly switch between ‘destructive’
and ‘recovery’ roles144, 145. As such, antagonists may be protective in early stages of the
insult progression but not later, highlighting the need for more specific anti-excitotoxic
strategies in which the physiological and neuroprotective roles of NMDARs are considered.
One promising strategy is the use of antagonists that preferentially block NMDARs in
excitotoxic scenarios and of pathologically-activated therapeutics, which are activated only
in the pathological state146. As an example of the former, memantine is a clinically well-
tolerated NMDAR antagonist with pharmacological properties that are suited to the
blockade of chronic NMDAR activity in pathological situations without interfering with
normal synaptic function146.
Memantine is an open channel blocker with a fast off-rate. Its uncompetitive nature results
in an effective blockade of chronic extrasynaptic NMDAR activity that is triggered by
elevated levels of glutamate126. Interestingly, due to its fast off-rate and voltage-dependent
binding properties memantine, when used at low doses, does not accumulate in the channel
and so does not substantially interfere with normal synaptic NMDAR activity 126, 147. As
such, it was proposed that low doses of memantine would not substantially affect the trans-
synaptic activation of synaptic NMDARs while allowing blockade of chronic extrasynaptic
NMDAR activation. This discrimination was recently demonstrated definitively in a study
on autaptic hippocampal cultures148. This study showed that the relative selectivity for
extrasynaptic NMDARs is sensitive to the concentration of memantine used, as increasing
the levels of memantine can lead to blockade of synaptic NMDARs (Figure 6b). Note,
however, that it has been shown that memantine also preferentially antagonizes GluN2C-
and GluN2D-containing NMDARs over GluN2A- and GluN2B-containing NMDARs under
physiological levels of Mg2+ 149. This should be taken into account when interpreting the
effects of memantine in systems in which GluN2C/D levels are substantial.
Nevertheless, the usefulness of memantine in preferentially uncoupling the NMDAR from
pro-death extrasynaptic NMDAR signalling has also been shown39, 43. For example, low
doses of memantine not only block NMDAR-dependent neuronal death that is induced by
toxic doses of NMDA without interfering with trans-synaptic NMDAR-dependent activation
of neuroprotective pathways; it does so in a manner which does not induce neuronal
degeneration in vivo, unlike ‘conventional’ antagonists such as MK-80143. The in vivo use
of memantine to antagonize neurodegenerative pathways that were characterized in vitro has
been elegantly demonstrated in the context of HD pathology44, 132. Treatment of YAC128
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mice with low dose memantine (1 mg/kg) from 2 months of age restored striatal phospho-
CREB levels to a level similar to that in wild-type animals, and prevented the motor learning
deficits that are normally apparent at 4 months of age132. A similar dosing regime also
prevented striatal loss in YAC128 mice at 12 months and prevented motor deficits44. The
protective effects of low-dose memantine were in sharp contrast with the effects of a much
higher dose (30 mg/kg), which blocks all NMDARs: an exacerbation of striatal cell loss and
motor deficits44. Given that memantine is a well-tolerated drug that has already been
approved for clinical use, it will be of great interest to see whether clinical trials of
memantine for HD reveal a reduction or delay of symptoms.
Concluding remarks
The survival and well-being of neurons requires synaptic activity and a dialogue between the
synapse and the nucleus. Ca2+ signals, initiated by synaptic NMDARs, propagate inward to
the nucleus and control genomic programmes that lead to a decrease in mitochondrial
vulnerability, reduced expression of pro-apoptotic factors including caspases, and a
strengthening of antioxidant defence systems. This form of acquired neuroprotection
increases the ‘neuronal survival reserve’ that enables neurons to cope with harmful
conditions in order to fulfil their function as computational units within neural circuits.
Extrasynaptic NMDARs antagonize the pro-survival signalling of synaptic NMDARs by
disturbing the communication between the synapse and the nucleus at various levels. Cell
death associated with neurodegenerative diseases (including AD and HD) may be partly due
to an imbalance of synaptic and extrasynaptic NMDAR signalling caused by synapse loss,
failure to transduce Ca2+ signals from the synapse to the nucleus, or by redistributions of
NMDARs from synaptic to extrasynaptic site. The antagonistic signalling of synaptic and
extrasynaptic NMDARs provides a novel conceptual basis for future developments of
neuroprotective therapies.
BOX1
Studying and defining synaptic and extrasynaptic NMDARs
Synaptic N-methyl-D-aspartate receptors (NMDARs) are classically defined as
functional receptors that are activated by glutamate released during low frequency
synaptic events 116, 150-153. This could include low-frequency evoked events,
spontaneous synaptic events and action potential-independent synaptic release of single
quanta of glutamate. Extrasynaptic NMDARs — that is, receptors that are not activated
during low-frequency synaptic events — can be found at various locations 6, including on
the cell body, the dendritic shaft, the neck of the dendritic spine and also adjacent to the
post-synaptic density (often referred to as perisynaptic) (see the figure, which shows
examples of immuno-electron-micrograph (EM) images of extrasynaptic NMDARs on
the dendritic shaft (A) and dendritic spine (B) in the hippocampal CA1 area of an adult
rat ; the NMDARs are labelled with immunogold (A) or immunoperoxidase (B) using an
NR1 antibody). Notably, in cultured neurons a proportion of NMDARs have the capacity
to move into and out of synaptic sites 113, 151, 154, particularly GluN2B-containing
NMDARs in young neurons 113 (although other studies have concluded that the mobility
of GluN2B- and GluN2A-containing NMDARs is similar 151). However, such NMDAR
mobility was not observed in acute slices, raising the question as to whether mobility is
more restricted in vivo 116.
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To study signalling associated with synaptic and extrasynaptic populations of NMDARs,
the receptors must be isolated for electrophysiological characterization, and stimulation
paradigms should be able to preferentially activate either pool. Preferential activation of
synaptic NMDARs in cultured hippocampal or cortical neurons can be initiated via
pharmacological removal of the GABAA receptor-mediated inhibition from the network.
This induces bursts of firing activity and results in tetrodoxin (TTX)-sensitive NMDAR-
dependent Ca2+ transients 50. A large portion of NMDARs are not activated by this
stimulation paradigm and are presumed to be predominantly extrasynaptic NMDARs 38.
Other techniques, such as the stimulation of afferents, are more suited to slice
preparations.
The general principle applied in studies of extrasynaptic NMDARs and the resultant
downstream signalling is to irreversibly block synaptic receptors before bath-applying the
agonist (glutamate or NMDA), so that the agonist will activate only the extrasynaptic
receptors. Synaptic NMDARs can be blocked by selectively inducing synaptic glutamate
release under conditions that activate synaptic NMDARs, but in the presence of the open
channel blocker MK-801 (blockade is essentially irreversible over the timescale of most
experiments). Brief pulses of high K+ or episodes of firing activity, or simply allowing
spontaneous action potential-dependent synaptic events can, in the presence of MK-801,
induce open channel blockade of synaptic NMDARs 38, 43, 115, 155. A slightly more
stringent approach involves only blocking those NMDARs that are exposed to glutamate
upon release of single quanta of glutamate 43. The isolation of extrasynaptic NMDAR
currents in hippocampal slice CA1 neurons can involve a similar strategy: MK-801 open-
channel blockade of synaptic NMDARs activated by low-frequency stimulation of the
stratum radiatum, followed by local uncaging of glutamate to activate extrasynaptic
NMDARs 116. Note that strategies aimed at selectively blocking synaptic NMDARs
require confirmation that little or no activation of extrasynaptic NMDARs takes place
over the timeframe of synaptic stimulation – such activation could be caused by
astrocytic glutamate release or elevated ambient glutamate due to nearby cellular
damage.
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Figure 1. χ-shaped model of NMDAR-dependent excitotoxicity
The schematic illustrates the opposing effects of increasing synaptic and extrasynaptic N-
methyl-D-aspartate receptor (NMDAR) activity on neuronal survival and resistance to
trauma. Hypoactivity of synaptic NMDARs is harmful to neurons. Enhancing synaptic
NMDAR activity triggers multiple neuroprotective pathways and this promotes neuronal
survival. Low levels of activation of extrasynaptic NMDARs have no effects on neuronal
survival but increasing the level of extrasynaptic NMDAR activity activates cell death
pathways and exacerbates certain neurodegenerative processes, thus reducing neuronal
survival.
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Figure 2. Neuroprotective pathways activated by synaptic NMDAR activity
Changes in gene expression underlie the long-lasting neuroprotection exerted by activation
of synaptic N-methyl-D-aspartate receptors (NMDARs). Changes include both the up-
regulation of protective genes — including anti-apoptotic genes, pro-survival genes and
genes involved in antioxidant responses — and the transcriptional suppression of pro-death
genes. This restricts the apoptotic potential of the neuron, reduces vulnerability of
mitochondria to insult-induced depolarization, and boosts intrinsic antioxidant defences
(these three effects are shaded in green). These changes boost neuronal resistance to a range
of traumata, including apoptotic, excitotoxic and oxidative insults (shaded in red), and
thereby prevent harmful outcomes (shaded in grey) such as apoptotic and non-apoptotic cell
death and cell dysfunction.ψm refers to mitochondrial membrane potential. ROS, reactive
oxygen species.
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Figure 3. Opposing effects of synaptic vs. extrasynaptic NMDAR signalling on gene expression
A. Opposing effects of synaptic vs. extrasynaptic NMDAR signalling on CREB-
dependent gene expression. The activation of cyclic-AMP response element binding
protein (CREB)-dependent gene expression by synaptic N-methyl-D-aspartate receptor
(NMDAR) activity is a multi-step process. CREB must be phosphorylated at serine-133 in
order to recruit its coactivator CREB binding protein (CBP) 52, 54; this phosphorylation is
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mediated by the fast-acting nuclear CaM kinase pathway (A) and the slower acting, longer
lasting Ras-ERK1/2 pathway (B) 50, 156, 157, both of which are promoted by activation of
synaptic NMDARs CBP is subject to Ca2+-mediated transactivation by nuclear Ca2+
dependent CaM kinase IV 58, 86, which phosphorylates CBP at serine-301 (C) 158. In
addition, nuclear translocation of transducer of regulated CREB activity (TORC) is a key
step in CREB activation. Synaptic NMDAR-induced Ca2+ signals promote TORC import
into the nucleus via calcineurin-dependent dephosphorylation (D) 159, 160. TORC acts at
least in part by assisting in the recruitment of CBP to CREB 161 (not shown). In contrast to
these CREB-activating signals of synaptic NMDARs, extrasynaptic NMDARs suppress
CREB activity 38, 89 through inactivation of the Ras-ERK1/2 pathway (E) 41 and the nuclear
translocation of Jacob, which promotes CREB dephosphorylation (F) 90.
B. Opposing effects of synaptic vs. extrasynaptic NMDAR signalling on FOXO-
dependent gene expression. Synaptic NMDAR activity suppresses FOXO activity by
promoting the Akt-mediated phosphorylation and nuclear export of FOXOs (A) 43, of which
FOXO1 and FOXO3 are the predominant neuronal subtypes. FOXO1 is also regulated
transcriptionally by FOXOs 78 and thus signals that cause FOXO export also result in
FOXO1 transcription being suppressed. By contrast, bath activation of NMDARs, which
also triggers extrasynaptic NMDAR activity, stimulates FOXO nuclear import (B), an event
that contributes, through promoting transcription of pro-death genes, to excitotoxic cell
death. 77 Synaptic NMDAR activity can exert a long-lasting block on this import signal (C)
77
, the mechanistic basis of which remains unclear.
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Figure 4. Synaptic NMDAR-dependent transcriptional changes have both anti-apoptotic and
anti-oxidant effects
A) Synaptic NMDAR signalling suppresses the intrinsic apoptosis cascade at multiple
levels. Synaptic N-methyl-D-aspartate receptor (NMDAR) activity protects neurons against
apoptosis in a manner that is independent of the type of cellular insult because it suppresses
the core apoptotic pathway. Transcriptional suppression of the BH3-only domain gene Puma
by activation of synaptic NMDARs is a key event upstream of cytochrome c release (A) 66,
67
. Up-regulation of a battery of nuclear Ca2+-regulated genes (green box) is also strongly
protective 47, 51 and probably also acts upstream of cytochrome c release, as it inhibits
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insult-induced mitochondrial membrane depolarization (B). Downstream of cytochrome c
release, transcriptional suppression of components of the caspase cascade, such as Apaf-1,
Caspase-9 and Caspase-3, also slows the apoptotic process (C) or raises the amount of
mitochondrial cytochrome c release that is required to initiate apoptosis (as cytochrome c’s
cytoplasmic target is Apaf-1) 67. Synaptic NMDAR activity also induces inactivation of the
pro-death transcription factors FOXO and p53 (D) 43, 66, 78, and the subsequent suppression
of the genes whose expression they regulate. Finally, transcription factors that have been
shown to be important targets for NMDAR-dependent pro-survival signals are shown,
namely CREB, NFAT and NFI-A (E) 47, 72, 73.
B) Synaptic NMDAR signalling boosts intrinsic antioxidant defences. A schematic
showing the effect of synaptic activity-induced changes in transcription on the thioredoxin
(Trx)-peroxiredoxin (Prx) system. The dotted arrows indicate activity-dependent signalling
events, which are collectively shaded in green. Briefly, reduction of peroxide levels is
executed via the transfer of electrons from NADPH to peroxides through the redox-active
sulfhydryl (-SH) groups of thioredoxin reductase, Trx and Prxs (the major two-cysteine Prx
sub-type is shown). The catalytic redox-active cysteine residue of Prx (Sc, red) reduces
peroxide, and is oxidized to cysteine sulfenic acid (SCOH). The resolving cysteine (SR,
green) of a different Prx molecule then forms a disulfide bond with Prx-SCOH, thereby
eliminating H2O. This intermolecular disulfide bond is then reduced by Trx, whose two-
cysteine active site is reduced by Trx reductase. However, if levels of peroxide are too high,
the – SCOH group becomes hyperoxidized to –SO2H (cysteine sulfinic acid). –SO2H is not a
substrate for the resolving cysteine –SCH or for Trx. Instead, sulfiredoxin (and possibly
sestrin 2) catalyses the reduction of hyperoxidized Prx-SO2H, returning it to the Trx cycle.
Synaptic activity triggers the events shown to both enhance Trx activity and boost the
reduction of hyperoxidized Prxs. These include the transcriptional activation of sulfiredoxin
and sestrin 2, and the transcriptional suppression of Txnip, the gene encoding a the Trx
inhibitor thioredoxin-interacting protein (Txnip). Bim (bcl2-interacting mediator of cell
death); Fasl (fas antigen ligand); Apaf1 (apoptotic peptidase activating factor 1); CREB
(cAMP responsive element binding protein); NFAT (nuclear factor of activated T-cells);
NFI-A (nuclear factor I/A); Atf3 (activating transcription factor 3); Bcl6 (B-cell leukemia/
lymphoma 6); Btg2 (B-cell translocation gene 2); Gadd45beta, GADD45gamma (growth
arrest and DNA damage induced gene 45 gamma and beta, respectively); Nr4a1 (nuclear
receptor subfamily 4, group A, member 1); Npas4 (neuronal PAS domain protein 4); Inhbb
(Inhibin beta-A).
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Figure 5. Activators and effectors of extrasynaptic NMDAR activity
Ischaemia results in activation of extrasynaptic N-methyl-D-aspartate receptor (NMDAR)
activation through reversed glutamate uptake from astrocytes (A) 130. Extrasynaptic currents
are also preferentially enhanced by ischaemia-induced death-associated protein kinase
(DAPK) activation (B) 131, as well as by mutant Huntingtin (mtHtt) in a mouse model of
Huntington’s disease (C) 132. Increased extrasynaptic (but not synaptic) NMDAR activity in
turn preferentially activates a number of pro-death pathways. ψm refers to mitochondrial
membrane potential, which is disrupted by extrasynaptic NMDAR activity.
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Figure 6. Clinical relevance of the balance between synaptic and extrasynaptic NMDAR activity
A. The balance of synaptic vs. extrasynaptic NMDAR signalling influences HD
pathology. Mutant Huntingtin (mtHtt) promotes neuronal dysfunction and death by
enhancing the expression and activity of extrasynaptic N-methyl-D-aspartate receptors
(NMDARs) (A) 132 and by directly blocking CREB/CBP-dependent PGC-1α transcription
(B) 134, 139, 140, as well as through other toxic mechanisms (C). Synaptic NMDAR activity
opposes mtHtt toxicity by promoting TRiC-dependent aggregation of mtHtt into non-toxic
inclusions (D) 44. Synaptic NMDAR activity also activates CREB-dependent PGC-1α
transcription (E) 44, 101, and enhances PGC-1α activity post-translationally via p38 (F)101.
PGC-1α itself protects neurons against mtHtt toxicity and extrasynaptic-NMDAR-
dependent excitotoxicity (G) 44, 101, 162. Extrasynaptic NMDAR activity reduces the
formation of non-toxic mtHtt inclusions by enhancing the expression of Rhes, a GTPase
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known to sumoylate and disaggregate mtHtt (H) 44. In addition, extrasynaptic NMDAR
signals suppress CREB-dependent gene expression 38 (not shown).
B. Effect of memantine on NMDARs. Low doses of memantine preferentially block the
chronic activation of extrasynaptic NMDARs (red line) by elevated levels of glutamate,
which may occur as a result of ischaemia or impaired glutamate homeostasis associated with
other disease processes. Low levels of memantine spare the trans-synaptic activation of
synaptic NMDARs (blue line). This specificity of the effect of memantine has been
demonstrated electrophysiologically 126, 147 as well as by studying downstream pro-death
and pro-survival signalling 39, 43, 44, 132.
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